The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Initiatives

News and Events

Funding Opportunity: Up-to $500K Available for Innovative Neurotechnologies

thumbnail

Funding Opportunity: Up-to $500K Available for Innovative Neurotechnologies

Two incubator hubs, CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are currently seeking proposals from academic and industry applicants who have emerging technologies that aim to improve the diagnosis and/or treatment of nervous system disorders.

A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space.

Program Details:

  • Awards up to $500K to help support development toward commercialization.

  • Mentorship from experienced commercialization experts

  • Support to address business, regulatory, clinical, and technical project aspects

 

The deadline has passed for this opportunity Pre-proposals were due no later than: October 24

Learn more about this program >

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, Cimit has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.